Effects of Subcutaneous Methotrexate in Patients with Refractory Uveitis and Chorioretinitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Methotrexate (MTX) is an immunosuppressive agent used to treat noninfectious inflammatory eye conditions and is generally administered orally for ocular inflammatory diseases. When used in rheumatological diseases, subcutaneous administration has been reported to show higher efficacy than oral administration. Therefore, this study aimed to evaluate the effect of subcutaneous MTX in patients with refractory uveitis or choroiditis who did not respond to other immunosuppressive agents. Methods: A retrospective case series study was performed between January and December 2018. Patients with uveitis or chorioretinitis who showed little to no treatment response for 6 months or more with conventional immunosuppressive agents were treated with MTX, administered subcutaneously. After 6 months of treatment, patients were evaluated to determine whether complete suppression of inflammation sustained for ≥28 days was achieved in both eyes and whether improvement can be confirmed by fluorescein angiography (FAG). Results: Subcutaneous MTX treatment was performed on 18 patients: 11 had intermediate uveitis and seven had posterior uveitis. In the intermediate uveitis patient group, five patients (50% of the group excluding one patient who dropped out) showed improvement in FAG and three patients (30%) showed complete suppression of inflammation. In the posterior uveitis group, two out of seven patients (excluding two patients who dropped out) showed an improvement, two patients in the group showed little change, and one patient showed aggravation of FAG findings. Conclusions: The study confirmed that in patients with uveitis or chorioretinitis who had a refractory response to treatment with other immunosuppressive agents, subcutaneous MTX showed improved treatment efficacy.
Abstract
Purpose: Methotrexate (MTX) is an immunosuppressive agent used to treat noninfectious inflammatory eye conditions and is generally administered orally for ocular inflammatory diseases. When used in rheumatological diseases, subcutaneous administration has been reported to show higher efficacy than oral administration. Therefore, this study aimed to evaluate the effect of subcutaneous MTX in patients with refractory uveitis or choroiditis who did not respond to other immunosuppressive agents. Methods: A retrospective case series study was performed between January and December 2018. Patients with uveitis or chorioretinitis who showed little to no treatment response for 6 months or more with conventional immunosuppressive agents were treated with MTX, administered subcutaneously. After 6 months of treatment, patients were evaluated to determine whether complete suppression of inflammation sustained for ≥28 days was achieved in both eyes and whether improvement can be confirmed by fluorescein angiography (FAG). Results: Subcutaneous MTX treatment was performed on 18 patients: 11 had intermediate uveitis and seven had posterior uveitis. In the intermediate uveitis patient group, five patients (50% of the group excluding one patient who dropped out) showed improvement in FAG and three patients (30%) showed complete suppression of inflammation. In the posterior uveitis group, two out of seven patients (excluding two patients who dropped out) showed an improvement, two patients in the group showed little change, and one patient showed aggravation of FAG findings. Conclusions: The study confirmed that in patients with uveitis or chorioretinitis who had a refractory response to treatment with other immunosuppressive agents, subcutaneous MTX showed improved treatment efficacy.
참고문헌 (17)
- Gangaputra S, "Methotrexate for ocular inflammatory diseases", Ophthalmology, 116, pp.2188~2198 (2009)
- Jabs DA, "Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders : recommendations of an expert panel", Am J Ophthalmol, 130, pp.492~513 (2000)
- Barry RJ, "Pharmacotherapy for uveitis : current management and emerging therapy", Clin Ophthalmol, 8, pp.1891~1911 (2014)
- Gomez-Gomez A, "Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: a systematic literature review", Semin Arthritis Rheum, 50, pp.1299~1306 (2020)
- Woo SJ, "Use of methotrexate for the treatment of ocular inflammation and uveitis", J Pharmacovigil, 1, pp.117~ (2013)
- Braun J, "Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial", Arthritis Rheum, 58, pp.73~81 (2008)
- Malaviya AN, "Methotrexate intolerance in the treatment of rheumatoid arthritis(RA) : effect of adding caffeine to the management regimen", Clin Rheumatol, 36, pp.279~285 (2017)
- Tugal-Tutkun I, "Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation(dual fluorescein and ICG angiographic scoring system for uveitis)", Int Ophthalmol, 30, pp.539~552 (2010)
- Jabs DA, "Immunosuppression for the uveitides", Ophthalmology, 125, pp.193~202 (2018)
- Hoekstra M, "Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis", J Rheumatol, 31, pp.645~648 (2004)
- Bianchi G, "Methotrexate and rheumatoid arthritis : current evidence regarding subcutaneous versus oral routes of administration", Adv Ther, 33, pp.369~378 (2016)
- Tukova J, "Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis", Clin Exp Rheumatol, 27, pp.1047~1053 (2009)
- Balis FM, "Pharmacokinetics of subcutaneous methotrexate", J Clin Oncol, 6, pp.1882~1886 (1988)
- Suhler EB, "Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis", Ophthalmology, 128, pp.899~909 (2021)
- Suhler EB, "Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study : VISUAL III", Ophthalmology, 125, pp.1075~1087 (2018)
- Anderson PJ, "Tumor necrosis factor inhibitors : clinical implications of their different immunogenicity profiles", Semin Arthritis Rheum, 34(5 Suppl1), pp.19~22 (2005)
- Heiligenhaus A, "Methotrexate for uveitis associated with juvenile idiopathic arthritis : value and requirement for additional anti-inflammatory medication", Eur J Ophthalmol, 17, pp.743~748 (2007)